Compare · DRNA vs VIE
DRNA vs VIE
Side-by-side comparison of Dicerna Pharmaceuticals, Inc. (DRNA) and Viela Bio, Inc. (VIE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRNA and VIE operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- DRNA carries a market cap of $2.96B.
- DRNA has more recent analyst coverage (14 ratings vs 0 for VIE).
- Company
- Dicerna Pharmaceuticals, Inc.
- Viela Bio, Inc.
- Price
- $38.23+0.61%
- -
- Market cap
- $2.96B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2019
- News (4w)
- 0
- 0
- Recent ratings
- 14
- 0
Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Latest DRNA
- Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
- SEC Form 15-12B filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form 4: Koppel Adam closing all direct ownership in the company
- SEC Form 4: Zeng Ling closing all direct ownership in the company
- SEC Form 4: Weissman James B closing all direct ownership in the company
- SEC Form 4: Smith Cynthia closing all direct ownership in the company
Latest VIE
- SEC Form 15-12B filed by Viela Bio, Inc.
- SEC Form SC 13D/A filed by Viela Bio, Inc.
- SEC Form 4: Yanling Cao disposed to the issuer $441,084,709 worth of Common Stock (8,322,353 units at $53.00)
- SEC Form 4 filed by Tyrell Rivers
- SEC Form 4 filed by Plc Astrazeneca
- SEC Form 4: Andreas Wicki disposed to the issuer $92,750,000 worth of Common Stock (1,750,000 units at $53.00)
- SEC Form 4: Edward Hu disposed to the issuer $220,542,381 worth of Common Stock (4,161,177 units at $53.00)
- SEC Form 4 filed by Ltd Meadow Boundless
- SEC Form 4: Mitchell Chan disposed to the issuer $1,987,500 worth of Common Stock (37,500 units at $53.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Jorn Drappa disposed to the issuer $10,741,033 worth of Common Stock (202,661 units at $53.00), decreasing direct ownership by 100% to 0 units